Poster presented by C. Pensec (Biofortis) at “PROBIOTA Congress” Amsterdam, “Onco Week” Toulouse and “4th R&D Business collaboration forum Europe” London

La Banque publique d’investissement soutien le projet IMODI
03/03/2013
Poster présenté par Th. Farge (Inserm U1037) au meeting de l’AACR dédié aux modèles PDX (USA, New Orleans, 11-14 février 2016)
11/02/2016

Poster presented by C. Pensec (Biofortis) at “PROBIOTA Congress” Amsterdam, “Onco Week” Toulouse and “4th R&D Business collaboration forum Europe” London

Pharmacological Testing of Chemotherapy in PDX Models: Impact on Gut Microbiota

Introduction

The national project IMODI (Innovative MODels Initiative) including 18 partners, aims to develop new patient-derived tumor graft (PDX) models that will be used for speed up innovative therapeutic approach development. Well characterized PDX models that come from 8 types of human cancer represent a suitable tool for preclinical evaluation of novel therapeutic strategies in cancer. The microbiota plays a major role in health and disease. In this project, Biofortis Mérieux NutriSciences explores gut microbiota association to cancer. The objective of this study is to identify the impact of pharmacological treatment on microbiota in PDX models, and especially on PDX models of lung cancer.
 
 
Share this